Chronic Back Pain

Chronic Back Pain Treatment | Ketamine for Chronic Back Pain

Chronic back pain is one of the most common reasons adults in the United States seek medical care, and one of the most common reasons they find themselves still in the same place years later. The imaging shows something. Or it shows nothing. Either way, the pain continues. The medications help partially, or they stop helping. Surgery was considered or performed, and the pain persisted.

For patients who have been through that cycle, chronic back pain ketamine treatment is one option that eventually comes into the conversation. Allay Health and Wellness offers chronic back pain ketamine therapy in Palm Beach Gardens, Florida, as a carefully evaluated off label clinical service for adults with chronic back pain who have not found adequate relief through established treatments. Every course of chronic back pain ketamine at Allay begins with a thorough evaluation, not a protocol. This page covers what chronic back pain is at a clinical level, why it is so frequently resistant to standard interventions, where chronic back pain ketamine fits in the treatment picture, what the evidence shows, and who may be appropriate for evaluation.

What Chronic Back Pain Actually Is

Chronic back pain is defined as back pain persisting for longer than three months. Beyond that, the category is broad enough to encompass multiple distinct conditions with different underlying mechanisms, different appropriate treatments, and different prognoses. Nociceptive chronic back pain arises from tissue damage, degenerative changes, structural problems such as disc herniation or facet joint arthritis, or inflammatory conditions. Pain here is generated by ongoing peripheral nociception and tends to correlate with imaging. Neuropathic chronic back pain arises from nerve damage or dysfunction, such as radiculopathy, post-surgical nerve damage, or arachnoiditis, and carries the characteristic features of neuropathic pain: burning, shooting, electric quality, allodynia, and hyperalgesia.

Nociplastic chronic back pain, sometimes called central sensitization pain, is back pain in which the central nervous system has become amplified in its pain processing. Imaging may show no structural abnormality proportional to pain intensity. This third category is where chronic back pain ketamine therapy has the most direct mechanistic application and the strongest clinical rationale. The National Institute of Neurological Disorders and Stroke maintains information on chronic pain and central sensitization for patients who want to understand this neurobiological context.

Why Chronic Back Pain Resists Standard Treatment

The challenge with chronic back pain is that the same treatment is frequently applied regardless of mechanism, and mechanism determines outcome. NSAIDs and muscle relaxants are appropriate for acute musculoskeletal back pain but have limited evidence for chronic presentations. Opioids produce tolerance, physical dependence, and in many patients with chronic back pain ketamine candidates, dose escalation with diminishing analgesic benefit over time. The Centers for Disease Control and Prevention’s clinical guidelines on opioid prescribing for chronic pain explicitly note that evidence for long term opioid therapy in chronic non cancer pain is limited and that risks increase substantially over time.

Interventional procedures including epidural steroid injections, facet joint blocks, radiofrequency ablation, and spinal cord stimulation provide meaningful relief for specific subpopulations but are not universally effective and are not indicated for all chronic back pain presentations. Surgery for degenerative disc disease has highly variable outcomes; a meaningful proportion of patients develop persistent post surgical pain, and patient selection is critical. Physical therapy and exercise rehabilitation have strong evidence and should be part of any chronic back pain management plan. Cognitive behavioral therapy for chronic pain, which addresses catastrophizing and pain related fear avoidance behavior, also has meaningful evidence.

Why Ketamine Is Clinically Relevant for Chronic Back Pain

Chronic back pain ketamine therapy has a stronger mechanistic argument for some chronic back pain presentations than others, and it is important to be specific about where that argument is strongest. For chronic back pain ketamine candidates whose pain is driven primarily by central sensitization, the mechanism is directly and specifically relevant. Ketamine is a potent NMDA receptor antagonist, and NMDA receptor activation is one of the primary mechanisms through which central sensitization is established and maintained. The wind up phenomenon, in which repetitive stimulation progressively lowers the pain threshold, is NMDA mediated. By blocking NMDA receptors, ketamine interrupts this process at a mechanistic level that gabapentinoids, opioids, and NSAIDs do not directly address.

For chronic back pain with a significant neuropathic component, such as persistent radiculopathy or post surgical neuropathic pain, ketamine’s effect on central sensitization is again relevant, for the same reasons that make neuropathic pain ketamine therapy clinically rational in that condition. For chronic back pain that is primarily structural and nociceptive, the argument is weaker. Ketamine does not remove a herniated disc or reverse joint degeneration. The rationale for chronic back pain ketamine in these presentations depends on whether a central sensitization component is present alongside the structural pathology, which is often the case in longstanding chronic pain regardless of original cause.

What the Evidence Shows

Chronic back pain ketamine treatment as a specific indication does not have the same volume of clinical trials as ketamine in depression or complex regional pain syndrome. Most of what exists comes from studies examining chronic low back pain within broader chronic pain populations, from case series, and from mechanistic extrapolation from neuropathic pain research. Small controlled studies have found that IV ketamine infusions reduced pain intensity in patients with chronic non cancer pain including back pain, with effects persisting beyond the acute drug period. A review examining ketamine in chronic pain across conditions published in Current Pharmaceutical Design found analgesic effects in chronic pain populations and noted the NMDA mechanism as particularly relevant to centralized pain presentations.

The American Society of Anesthesiologists and the American Society of Regional Anesthesia have published consensus guidance on ketamine for chronic pain, noting its utility in centralized and refractory pain conditions while emphasizing the importance of patient selection, appropriate clinical context, and ongoing monitoring.

The honest summary: chronic back pain ketamine has a plausible, well matched mechanism for central sensitization presentations and encouraging preliminary evidence in chronic pain populations broadly. It does not have large randomized controlled trials specific to chronic back pain.

The Off Label Reality

Chronic back pain ketamine therapy is an off label use. The FDA has not approved IV ketamine for chronic back pain or any pain condition. Its only approved indication is as a general anesthetic. Spravato (esketamine) is not approved for any pain condition. Its approval covers treatment resistant depression in adults and depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior. It is not used at Allay Health and Wellness for pain.

Off label prescribing is legal and standard across medicine. Many interventions now considered standard of care for chronic pain, including the use of antidepressants and anticonvulsants for neuropathic pain, were adopted via off label clinical practice before supporting trials were completed. Patients considering chronic back pain ketamine treatment should understand the regulatory status, the current evidence base, and realistic expectations before evaluation. Any clinic marketing chronic back pain ketamine as proven or well established is misrepresenting the literature.

What Chronic Back Pain Ketamine Treatment Involves at Allay

Every patient considering chronic back pain ketamine treatment at Allay Health & Wellness begins with an individualized evaluation before any treatment recommendation is made. Our process considers the nature of your back pain, previous care, overall health, and appropriate monitoring throughout treatment.

• Evaluation: Intake covers your diagnosis and pain history, identified structural, neuropathic, or nociplastic components, previous treatments with doses and durations, surgical history, co occurring psychiatric conditions, cardiovascular health, and substance use history. No referral is required. Bring available imaging reports, operative notes, and relevant specialist records.
• The Sessions: IV ketamine is administered slowly through an intravenous line in a private, monitored room. A licensed clinician remains present and monitors vital signs throughout treatment. Pain protocols may involve longer infusion durations than psychiatric protocols. For chronic back pain ketamine treatment, the number and frequency of infusions depend on your clinical presentation and response. During consultation, we also discuss how many ketamine therapy sessions may be needed and why pain protocols can follow a different treatment schedule from psychiatric care.
• After Sessions: You may not drive after an infusion. A responsible adult must arrange transportation home, and your clinical team will provide individualized post treatment instructions.

Chronic Back Pain, Mood, and the Amplification Cycle

Chronic back pain and depression co occur at substantially elevated rates. Both conditions are common, but their overlap can reflect interacting biological, functional, and psychological factors that may intensify the overall symptom burden. Pain can contribute to depression through sleep disruption, functional limitations, and the psychological strain of persistent symptoms. Depression can also influence the experience of pain through changes in pain processing, reduced activity, sleep disturbance, and catastrophizing, which can be associated with greater pain intensity and disability.

For patients experiencing both chronic back pain and depression, each condition should be evaluated individually rather than assuming that treating one will resolve the other. When significant depressive symptoms are present, ketamine therapy for depression may become part of a separate clinical discussion based on diagnosis, treatment history, and individual eligibility. This coordinated approach allows Allay Health & Wellness to consider relevant mental health needs alongside ongoing pain management. Daniel Cartledge, M.D., our clinical consultant, is double board certified in pain management and physical medicine and rehabilitation. His experience is particularly relevant when pain and psychiatric concerns overlap, and patients can learn more about his background and the credentials of the broader Allay Health & Wellness clinical team before scheduling an evaluation.

Safety, Risks, and Potential Side Effects

Every patient evaluated for chronic back pain ketamine treatment receives a clear explanation of potential risks, side effects, and treatment limitations before anything is scheduled. Allay Health & Wellness also reviews individual medical and medication factors that may influence treatment safety.

• Dissociation: Ketamine can cause temporary changes in perception, awareness, time, space, or sense of self. Clinical staff monitor these effects throughout every infusion.
• Sedation: Ketamine may cause sedation and impaired alertness. You may not drive after treatment and must arrange transportation home.
• Blood Pressure and Heart Rate Changes: Temporary increases in blood pressure and heart rate can occur. Vital signs are monitored before, during, and after treatment.
• Nausea: Nausea may occur during longer pain management infusions. Clinicians may consider appropriate measures to manage nausea based on individual history and clinical judgment.
• Psychological Effects: Some patients experience vivid perceptual changes, anxiety, or heightened emotional responses. Clinical staff remain present throughout every infusion.
• Controlled Substance Considerations: Ketamine is a federally regulated Schedule III controlled substance. Dependency and misuse risks are reviewed during intake, particularly when patients have a history of opioid use. Understanding whether ketamine can be addictive and how supervised medical use affects that risk is an important part of informed treatment planning.

No outcome from chronic back pain ketamine treatment can be predicted or guaranteed. Responses vary among individuals and across different causes and presentations of chronic back pain.

Who May Be a Candidate

A clinical evaluation is required before Allay Health & Wellness makes any treatment recommendation. Adults who may be considered for chronic back pain ketamine therapy generally have documented persistent back pain with possible neuropathic or centralized pain features and an inadequate response to established treatment options. Continued participation in appropriate physical therapy, psychological support, or other recommended care may remain an important part of the overall treatment plan.

Medical and psychiatric history also influences eligibility. Conditions such as uncontrolled hypertension or active psychosis may affect whether ketamine is appropriate. Because ketamine is a federally regulated Schedule III controlled substance, substance use history, including current or previous opioid use, is reviewed carefully and without judgment as part of the clinical assessment.

Allay Health & Wellness treats adults age 18 and older exclusively. Patients with questions about medications, monitoring, side effects, or the evaluation process can review our ketamine therapy FAQ before consultation. Individual factors such as medical history, current medications, previous treatment response, and potential contraindications ultimately determine who may be eligible for ketamine therapy.

FAQs about Chronic Back Pain Ketamine Treatment

1. Is ketamine FDA-approved for chronic back pain?
   No. Chronic back pain ketamine treatment is an off-label use. The FDA has not approved IV ketamine for chronic back pain or any pain condition. Research has examined ketamine for certain neuropathic and centralized pain conditions, but evidence specific to chronic back pain remains limited.
2. My imaging shows a herniated disc. Will ketamine help?
   Ketamine does not correct a herniated disc or other structural spinal condition. If structural pathology is the primary source of pain, other treatments may be more appropriate. When chronic back pain also involves neuropathic or centralized pain mechanisms, chronic back pain ketamine treatment may be discussed during an individualized clinical evaluation. No specific response can be predicted.
3. I have taken opioids for years. Can I still be evaluated?
   Yes. A history of opioid use does not automatically exclude you from evaluation. Our clinicians review current and previous opioid use, medication history, substance use history, and overall pain management plan when determining whether treatment may be appropriate. Do not change or stop prescribed opioids without guidance from your prescribing clinician.
4. Does insurance cover chronic back pain ketamine treatment?
   Off-label IV ketamine is generally not covered by most insurance plans. Allay Health & Wellness accepts Medicare, Cigna, UnitedHealthcare, and Aetna for eligible services. Our team verifies available benefits and provides anticipated cost information before treatment is scheduled. Coverage varies by plan and is never guaranteed.
5. How many ketamine infusions would I need?
   Treatment schedules vary according to the patient’s condition, medical history, clinical response, and treatment plan. Chronic pain protocols may involve a series of infusions, but no specific number of sessions can guarantee improvement or predict how long any response may last.
6. Do I need a referral?
   No referral is required. Bring available back pain documentation, imaging reports, previous treatment records, operative notes when applicable, and a complete list of current medications. These records can help our clinical team conduct a more informed evaluation for chronic back pain ketamine treatment.

Schedule a Consultation for Chronic Back Pain Ketamine Treatment

If established treatments have not provided adequate improvement for your chronic back pain, Allay Health & Wellness is available to discuss whether chronic back pain ketamine treatment may have a place in your care. Our clinical team reviews your diagnosis, previous treatments, current medications, imaging history, and overall health before making any recommendation. We explain the off label status of IV ketamine, available evidence, potential risks, and treatment limitations so you can make an informed decision.

Patients who want to understand the clinical basis for treatment can review the peer reviewed research that informs our approach and learn more about the credentials and experience of the clinicians involved in their care. Allay Health & Wellness treats adults age 18 and older exclusively.

Address: 11000 Prosperity Farms Rd, Suite 101, Palm Beach Gardens, FL 33410
Email: [email protected]
Phone: (561) 421-6444

Contact Allay Health & Wellness to schedule a consultation and discuss whether further evaluation may be appropriate.

Medical Disclaimer: This content is educational only and not a substitute for professional medical advice, diagnosis, or treatment. IV ketamine for chronic back pain is an off-label use, not FDA-approved for any pain condition. Spravato is not approved for pain. First-line treatments should be completed before off-label options are considered. Evidence for ketamine in chronic back pain is preliminary. Individual outcomes vary and are never guaranteed. Treatment requires evaluation by a licensed clinician. Allay treats adults 18 and older.

Reviewed by Nicholas Marino, MBA, Co-Founder and CEO, Allay Health and Wellness